Literature DB >> 15142224

Psychiatric comorbidity in a population of Parkinson's disease patients.

A Nuti1, R Ceravolo, A Piccinni, G Dell'Agnello, G Bellini, G Gambaccini, C Rossi, C Logi, L Dell'Osso, U Bonuccelli.   

Abstract

Behavioural disturbances are frequently observed in Parkinson's disease (PD), including mood and anxiety disorders. The existence of a comorbidity between such psychiatric disorders in PD patients has been suggested only in a few studies. To assess the prevalence of mood and anxiety disturbances, and the rate of comorbidity of such disorders in PD. Secondary aim was to correlate the prevalence of psychiatric disorders in PD with age, sex, laterality of motor symptomatology, clinical features, severity of disease, age of onset and PD duration, and anti-parkinsonian therapy. Ninety consecutive PD outpatients, and 90 age- and sex-matched controls were included. All PD patients enrolled were non-fluctuating (21 de novo, 69 treated with levodopa or dopamine agonists). PD patients and controls with Mini Mental State Examination score <23 were excluded. Psychiatric diagnosis was performed by semistructured interview according with DSM-IV criteria and the severity of depressive and anxious symptoms was rated with clinical rating scales. Major depression was found in 21.1% PD patients vs. 3.3% controls (P < 0.01, chi-square analysis), dystimia in 18.8% PD patients vs. 4.4% controls (P < 0.05), panic disorders in 30% PD patients vs. 5.5% controls (P < 0.01). No difference in the prevalence of other anxiety disorders was observed between the two groups. The comorbidity of mood and anxiety disorders was found in 19.3% PD patients vs. 8.6% controls (P < 0.01). No correlation was reported between the prevalence of behavioural disturbances and any of the demographic, clinical or pharmacological data taken into account. Our findings might suggest the existence of a wide spectrum of psychiatric disorders in PD ranging from pure depressive disorders, comorbid depressive and anxiety disorders, and pure anxiety disorders, presumably linked to the same neurobiological substrate.

Entities:  

Mesh:

Year:  2004        PMID: 15142224     DOI: 10.1111/j.1468-1331.2004.00781.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  48 in total

Review 1.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

2.  Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease.

Authors:  Gregory M Pontone; James R Williams; Karen E Anderson; Gary Chase; Susanne A Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Peter V Rabins; Howard D Weiss; Laura Marsh
Journal:  Mov Disord       Date:  2009-07-15       Impact factor: 10.338

3.  The relation of anxiety and cognition in Parkinson's disease.

Authors:  Gretchen O Reynolds; Kristine K Hanna; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Neuropsychology       Date:  2017-04-20       Impact factor: 3.295

4.  Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Authors:  Daniela Di Giuda; Giovanni Camardese; Anna Rita Bentivoglio; Fabrizio Cocciolillo; Arianna Guidubaldi; Lorella Pucci; Isabella Bruno; Luigi Janiri; Alessandro Giordano; Alfonso Fasano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-14       Impact factor: 9.236

Review 5.  Approach to diagnosis of Parkinson disease.

Authors:  Christopher Frank; Giovanna Pari; John P Rossiter
Journal:  Can Fam Physician       Date:  2006-07       Impact factor: 3.275

Review 6.  Anxiety in Parkinson's disease: identification and management.

Authors:  Jack J Chen; Laura Marsh
Journal:  Ther Adv Neurol Disord       Date:  2014-01       Impact factor: 6.570

Review 7.  Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson's disease.

Authors:  Atami Sagna; Joseph J Gallo; Gregory M Pontone
Journal:  Parkinsonism Relat Disord       Date:  2014-04-01       Impact factor: 4.891

Review 8.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

9.  Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects.

Authors:  Gregor Hasler; Stephen Fromm; Paul J Carlson; David A Luckenbaugh; Tracy Waldeck; Marilla Geraci; Jonathan P Roiser; Alexander Neumeister; Noah Meyers; Dennis S Charney; Wayne C Drevets
Journal:  Arch Gen Psychiatry       Date:  2008-05

Review 10.  Psychiatric symptoms in Parkinson's disease.

Authors:  Frank Schneider; Astrid Althaus; Volker Backes; Richard Dodel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.